TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 8.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 973,466 shares of the company’s stock after purchasing an additional 72,967 shares during the quarter. Geode Capital Management LLC owned 1.84% of TScan Therapeutics worth $4,849,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in TCRX. Barclays PLC grew its position in TScan Therapeutics by 341.1% during the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after buying an additional 44,903 shares during the period. XTX Topco Ltd acquired a new stake in shares of TScan Therapeutics during the 3rd quarter valued at about $112,000. Wellington Management Group LLP increased its stake in shares of TScan Therapeutics by 38.9% in the 3rd quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock valued at $629,000 after purchasing an additional 35,404 shares in the last quarter. State Street Corp raised its holdings in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after purchasing an additional 148,414 shares during the period. Finally, Stifel Financial Corp boosted its position in TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after purchasing an additional 3,733 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TCRX. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Monday, December 23rd. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

TScan Therapeutics Stock Down 0.6 %

Shares of TCRX opened at $3.07 on Friday. The stock has a 50 day moving average price of $4.12 and a 200 day moving average price of $5.29. TScan Therapeutics, Inc. has a one year low of $2.60 and a one year high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The stock has a market capitalization of $163.85 million, a price-to-earnings ratio of -2.90 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Equities research analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.